Harmanjeet Kaur1, J S Thakur1, Ronika Paika1, Shailesh M Advani2. 1. Department of Community Medicine & School of Public Health, PGIMER, Chandigarh, India. 2. Cancer Prevention and Control Program, Georgetown University School of Medicine, Georgetown University, Washington DC, USA.
Abstract
BACKGROUND: The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality. METHODS: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients. RESULTS: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)]. CONCLUSION: Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services.<br />.
BACKGROUND: The evidence has shown that SARS CoV-2 infectedpatients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancerpatients risks associated with other underlying comorbidities might vary from those in non-cancerSARS CoV-2 infectedpatients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancerpatients with SARS CoV-2 infection and their impact on mortality. METHODS: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancerpatients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancerpatients. RESULTS: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancerpatients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)]. CONCLUSION: Our results indicates that the mortality in SARS-CoV-2 infected cancerpatients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancerpatients presenting with SARS-COV-2, on their initial contact with health services.<br />.
Entities:
Keywords:
COVID-19; Carcinoma; Case fatality; Prevalence; review
Authors: Deborah S Hasin; David S Fink; Mark Olfson; Andrew J Saxon; Carol Malte; Katherine M Keyes; Jaimie L Gradus; Magdalena Cerdá; Charles C Maynard; Salomeh Keyhani; Silvia S Martins; Ofir Livne; Zachary L Mannes; Scott E Sherman; Melanie M Wall Journal: Drug Alcohol Depend Date: 2022-03-03 Impact factor: 4.852